Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016


  • Products Id :- GDHC3719CTIDB
  • |
  • Pages: 208
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016" provides an overview of Relapsed Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials 28

Prominent Drugs 30

Clinical Trial Profile Snapshots 31

Appendix 205

Abbreviations 205

Definitions 205

Research Methodology 206

Secondary Research 206

About GlobalData 207

Contact Us 207

Disclaimer 207

Source 208

List of Figures

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14

Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

GlobalData Methodology 206

List of Tables

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2016* 6

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14

Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

F. Hoffmann-La Roche Ltd.

Celgene Corporation

Novartis AG

Johnson & Johnson

AstraZeneca Plc

GlaxoSmithKline Plc

Gilead Sciences, Inc.

Infinity Pharmaceuticals, Inc.

Sanofi

select a license
Single User License
USD 2500 INR 179800
Site License
USD 5000 INR 359600
Corporate User License
USD 7500 INR 539400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com